A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 E/K mutant advanced melanoma

Pigment Cell Melanoma Res. 2019 Jul;32(4):603-606. doi: 10.1111/pcmr.12777. Epub 2019 Apr 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacokinetics
  • Aminopyridines / therapeutic use*
  • Disease Progression
  • Humans
  • Melanoma / diagnostic imaging
  • Melanoma / drug therapy*
  • Melanoma / genetics*
  • Melanoma / pathology
  • Morpholines / pharmacokinetics
  • Morpholines / therapeutic use*
  • Mutation / genetics*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Vemurafenib / therapeutic use*

Substances

  • Aminopyridines
  • Morpholines
  • NVP-BKM120
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf

Associated data

  • ClinicalTrials.gov/NCT01512251